Tag: attr cm treatment trends

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, and What Factors Will Drive It?

The market for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment has witnessed exponential growth in recent times. It is projected to inflate from $10.36 billion in 2024 to $13.29 billion by the year 2025, signifying a Compound Annual Growth Rate (CAGR) of 28.2%. Factors such as the upward trend in occurrences of Transthyretin Amyloid Cardiomyopathy, heightened cases of Transthyretin Amyloidosis in the elderly population, increased awareness amongst healthcare practitioners and patients, and enhancements in healthcare services have all catalyzed this growth during the historic period.

The market size for the treatment of transthyretin amyloid cardiomyopathy (attr-cm) is predicted to significantly increase in the forthcoming years. It’s projected to reach$35.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 27.8%. The growth during this predicted period can be credited to a rise in transthyretin amyloidosis cases, an increase in neuropathic disorder diagnoses, an ageing demographic, higher demand for specific drugs to manage the symptoms of this rare disease, and an overall increase in healthcare demand. Key trends for the forecast period comprise novel diagnostic technologies, breakthrough techniques for therapy management, innovative and targeted treatments for transthyretin amyloidosis, and advancements in diagnostic and cardiac MRI techniques.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

The escalating incidence of chronic illnesses is anticipated to stimulate the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, which are long-term ailments that evolve gradually and last for more than a year, often necessitating ongoing medical attention. This upsurge in chronic conditions can be linked to factors like increasing age, sedentary ways of life, unhealthy eating habits, a rise in obesity, and contact with environmental toxins. The treatment for transthyretin amyloid cardiomyopathy works by stabilizing transthyretin, reducing the accumulation of amyloid, enhancing heart performance, and mitigating symptoms for optimal handling of associated chronic disorders. For example, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in September 2023, that there were 41 million deaths, representing 74% of deaths caused by non-communicable diseases (NCDs) or chronic ailments each year. Worldwide, cardiovascular diseases contributed to 17.9 million deaths, cancer to 9.3 million deaths, chronic respiratory diseases to 4.1 million deaths, and diabetes to 2.0 million deaths. Consequently, the prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Which Key Market Segments Comprise the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market and Drive Its Revenue Growth?

The transthyretin amyloid cardiomyopathy (attr-cm) treatmentmarket covered in this report is segmented –

1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types

2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis

3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis; Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs

3) By RNAi Therapy: Patisiran; Vutrisiran

4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp

Which Areas Are Leading Regions in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Expansion Across the Globe?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theTransthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Direction?

Major firms in the ATTR-CM treatment market are putting their efforts into the development of groundbreaking therapies for ATTR-CM, like oral medication that aims to stabilize TTR proteins or minimize the accumulation of amyloid fibril in the heart. Oral prescription medication, usually distributed in the form of tablets, capsules, or liquid solutions, is a category of drugs recommended by trained healthcare professionals for consumption orally. For example, the U.S. Food and Drug Administration granted approval to the US biotech firm, BridgeBio Pharma Inc., in November 2024 for its drug, Attruby (acoramidis), designed for treating adults with ATTR-CM. It imparts stability to the TTR protein, thereby decreasing the rate of hospitalizations and fatalities linked to heart conditions. Clinical studies suggest that the drug is well-tolerated and offers quick benefits by addressing the underlying cause of the illness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

How Is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Conceptually Defined?

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Changed, over the years?

The market size for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment has experienced a significant increase in the recent past. The market is projected to expand from $10.36 billion in 2024 to $13.32 billion in 2025 showcasing a compound annual growth rate (CAGR) of 28.5%. This increment during the past years can be credited to the growing occurrence of transthyretin amyloid cardiomyopathy, high prevalence of transthyretin amyloidosis among the aged population, heightened alertness among healthcare providers and patients, along with the growth in health consciousness and improvement in healthcare services.

How Much Will the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Be Worth in 2029?

In the ensuing years, the market size for transthyretin amyloid cardiomyopathy (ATTR-CM) therapy is projected to witness massive expansion. The market is set to hit a value of $35.93 billion in 2029, with a compound annual growth rate (CAGR) of 28.2%. This anticipated growth within the projected period can be ascribed to the escalating occurrence of transthyretin amyloidosis, an increase in the diagnosis of nerve disorders, surge in the aging populace, rise in requisite for specific medications for the mitigation of symptoms of this rare ailment, and a boosted demand for healthcare. The forecast period will see prominent trends such as the advent of new diagnostic technology, the creation of novel methods for therapy management, targeted and innovative treatments for transthyretin amyloidosis, and breakthroughs in diagnostic techniques inclusive of cardiac MRI techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

Which is the Largest Company in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

What Are the Main Market Drivers in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?

The escalating occurrence of chronic conditions is anticipated to spur the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic illnesses are enduring issues that evolve over time and persist for a year or longer, often necessitating frequent medical attention. Factors contributing to the increase in chronic diseases include aging populations, inactive lifestyles, unhealthy food habits, rising obesity levels, and contact with environmental contaminants. The administration of transthyretin amyloid cardiomyopathy treatment aids in stabilizing transthyretin, alleviating amyloid deposition, enhancing cardiac performance, and relieving symptoms to more effectively control related chronic illnesses. For example, in September 2023, as per the data from the World Health Organization, a specialized agency of the United Nations based in Switzerland, there were 41 million deaths, or 74% of total deaths, caused by non-communicable diseases (NCDs) or chronic conditions annually. Worldwide, cardiovascular diseases accounted for 17.9 million deaths, cancer for 9.3 million, chronic respiratory illnesses for 4.1 million, and diabetes for 2.0 million. Hence, the escalating occurrence of chronic conditions is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp

How Is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segments Structured?

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs

3) By RNAi Therapy: Patisiran, Vutrisiran

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

What Strategic Trends Are Transforming the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

Top players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment landscape are centering their efforts on creating cutting-edge meds for ATTR-CM, such as oral drugs tailored to balance and steady transthyretin (TTR) proteins or decrease the accumulation of amyloid fibril in the heart. Oral medications generally refer to treatments orally administered, usually in the guise of tablets, capsules, or liquid concoctions, prescribed by health practitioners. To illustrate, in November 2024, BridgeBio Pharma Inc., a biotech firm based in the US, secured the green light from the U.S. Food and Drug Administration for Attruby (acoramidis), designed for adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This treatment stabilizes the TTR protein, and diminishes cardiac-related fatalities and hospital admissions. Results from clinical trials have indicated that it’s well received and rapidly beneficial, specifically addressing the underlying issue of the disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

Which Global Regions Offer the Highest Growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

This Report Delivers Insight On:

1. How big is the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, and how is it changing globally?

2. Who are the major companies in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, and how are they performing?

3. What are the key opportunities and risks in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market right now?

4. Which products or customer segments are growing the most in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?

5. What factors are helping or slowing down the growth of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#How Has The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment has seen a significant uptick in recent years. Projections indicate growth from $10.36 billion in 2024 to $13.32 billion in 2025 with a compound annual growth rate (CAGR) of 28.5%. The expansion in the preceding years can be associated with a growing number of transthyretin amyloid cardiomyopathy cases, an uptick in transthyretin amyloidosis amongst the elderly population, increased awareness amongst healthcare providers and patients, and the development and enhancement of healthcare services._x000D_

_x000D_

The market size for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is predicted to experience remarkable growth in the approaching years, skyrocketing to $35.93 billion by 2029, growing at a compound annual growth rate (CAGR) of 28.2%. Factors fueling this expansion during the forecast period include the rising incidence of transthyretin amyloidosis, an increase in diagnoses of neuropathic conditions, a growing elderly population, a rising demand for specific medication to treat this rare disorder’s symptoms, and a surge in healthcare needs. Noteworthy trends expected during the forecast period include the emergence of novel diagnostic technologies, the creation of innovative approaches for therapy management, new and targeted treatments for transthyretin amyloidosis, as well as advancements in diagnostic methods, such as cardiac MRI techniques._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?#_x000D_

The increase in chronic conditions is projected to boost the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic diseases, which are long-term and advance at a gradual pace, often enduring over a year and needing continuous healthcare, are increasingly becoming prevalent. This rise is due to a variety of reasons such as an aging population, inactive lifestyles, unhealthy food habits, a growing obesity epidemic, and exposure to environmental pollutants. Treatments for transthyretin amyloid cardiomyopathy work by stabilizing transthyretin, minimizing amyloid accumulation, enhancing cardiac performance, and easing symptoms to manage related chronic diseases more effectively. For example, as per the World Health Organization, a specialized agency of the United Nations based in Switzerland, in September 2023, out of the 41 million deaths, 74% were due to non-communicable diseases (NCDs) or chronic diseases, annually. Worldwide, cardiovascular diseases claimed 17.9 million lives, cancer caused 9.3 million deaths, chronic respiratory diseases resulted in 4.1 million deaths and diabetes was responsible for 2.0 million fatalities. Consequently, the upswing in chronic illness prevalence is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market._x000D_

_x000D_

#Which Primary Segments of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Are Driving Growth and Industry Transformations?#_x000D_

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types_x000D_

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis_x000D_

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal_x000D_

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs_x000D_

3) By RNAi Therapy: Patisiran, Vutrisiran_x000D_

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?# Market?#_x000D_

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?#_x000D_

Key players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment marketplace are concentrating on the creation of groundbreaking therapies for ATTR-CM, including orally administered prescription medications designed to stabilize transthyretin (TTR) proteins and minimize amyloid fibril accumulation in the heart. Oral prescription drugs, usually in the form of tablets, capsules, or liquid solutions, are those prescribed by healthcare professionals to be ingested orally. For instance, BridgeBio Pharma Inc., a biotech firm based in the United States, got approval from the U.S. Food and Drug Administration in November 2024 for Attruby (acoramidis) which is intended for the treatment of adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This medication works by stabilizing the TTR protein, leading to a decrease in heart-related deaths and hospitalizations. Clinical studies suggest that this treatment is well-tolerated and offers quick benefits by directly addressing the disease’s root cause._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?#_x000D_

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

The growing prevalence of chronic diseases is anticipated to drive the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic diseases are long-term conditions that develop gradually and persist for extended periods, often requiring ongoing medical attention. The increase in chronic diseases is linked to factors such as aging populations, sedentary lifestyles, poor diets, rising obesity rates, and exposure to environmental pollutants. ATTR-CM treatment aids by stabilizing transthyretin, reducing amyloid accumulation, enhancing heart function, and alleviating symptoms to better manage associated chronic conditions. For example, in September 2023, the World Health Organization reported that chronic diseases accounted for 74% of all deaths globally, with 41 million deaths annually. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the increasing prevalence of chronic diseases is driving the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

#What is the Growth Potential of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, and How Will It Perform by 2034?

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market has expanded exponentially, growing from $10.36 billion in 2024 to $13.32 billion in 2025 at a CAGR of 28.5%. Factors contributing to this growth include the rising prevalence of ATTR-CM, an increasing geriatric patient population, heightened awareness among healthcare professionals and patients, and improvements in healthcare services.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to experience exponential growth, reaching $35.93 billion by 2029, with a CAGR of 28.2%. The rapid growth will be driven by an increasing prevalence of transthyretin amyloidosis, improved diagnosis of neuropathic disorders, a growing aging population, rising demand for targeted drugs to manage symptoms of this rare condition, and increasing demand for healthcare services. Major trends anticipated include advancements in diagnostic technologies, the development of innovative therapy management techniques, the introduction of targeted treatments for transthyretin amyloidosis, improvements in diagnostic methods, and the adoption of cardiac MRI techniques.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

What Are the Most Significant Market Trends Transforming theTransthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

In the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, companies are developing oral medications to target and stabilize transthyretin proteins or reduce amyloid fibril buildup in the heart. For example, in November 2024, BridgeBio Pharma received FDA approval for Attruby (acoramidis), an oral medication that stabilizes the transthyretin protein and reduces heart-related complications from ATTR-CM, showing rapid benefits for patients.

What Are the Top Market Players Propelling the Growth of theTransthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?

Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

Which Primary Segments of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Are Driving Growth and Industry Transformations?

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs

3) By RNAi Therapy: Patisiran, Vutrisiran

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?# Market?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2025, By The Business Research Company:

Hepatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Hepatitis Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the market?

The market size of treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) has seen a significant increase in recent times. The market, which will reach $10.36 billion in 2024, is projected to increase to $13.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.5%. The impressive growth seen in the historical period is due to several factors such as the increasing occurrence of transthyretin amyloid cardiomyopathy, rising incidence of transthyretin amyloidosis in elderly patients, enhanced awareness among healthcare practitioners and patients, and progress in healthcare services and awareness initiatives.

What will be the market size in the future?

In the coming years, an extraordinary surge is expected in the market size for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The market will shoot up to a whopping $35.93 billion by 2029, growing at an impressive CAGR of 28.2%. The surge in the forecast period can be associated with factors like the growing occurrence of transthyretin amyloidosis, escalation in neuropathic disorder diagnosis, an increasing aging population demographic, rising request for specific drugs to treat the rare disorder symptoms, coupled with an increased demand in the healthcare sector. The future will be marked by significant trends, such as the emergence of new diagnostic technologies, the inception of inventive therapy management techniques, novel and focused treatments for transthyretin amyloidosis, and advancements in diagnostic and cardiac MRI techniques.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

What are the major factors driving growth in the market?

The escalating occurrence of long-lasting ailments, which evolve slowly and often necessitate ongoing healthcare support, is anticipated to spur the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. The increased occurrence of such conditions could be due to factors including an aging populace, inactive lifestyles, poor dietary habits, growing obesity issues, and the presence of environmental pollutants. Transthyretin amyloid cardiomyopathy treatment contributes by steadying transthyretin, lowering amyloid accumulation, enhancing cardiac function, and easing symptoms to more effectively manage associated chronic diseases. As per the World Health Organization, a United Nations-specialized agency based in Switzerland, there were 41 million deaths in September 2023, accounting for 74% of annual deaths caused by non-communicable diseases or chronic ailments. On a global scale, cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes caused 17.9 million, 9.3 million, 4.1 million, and 2.0 million deaths respectively. Hence, the ever-increasing occurrence of chronic diseases is powering the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

What key areas define the segmentation of the global market?

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs

3) By RNAi Therapy: Patisiran, Vutrisiran

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

Who are the dominant players expanding their reach in the market?

Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

What key trends are currently impacting the market’s development?

Leading corporations in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating their efforts on creating new and unique treatments for ATTR-CM. This includes oral medication prescriptions that target and stabilize transthyretin (TTR) proteins or decrease the accumulation of amyloid fibril in the heart. Oral prescription medication, often in the form of capsules, tablets, or liquid solutions, is typically prescribed by a healthcare provider. For example, BridgeBio Pharma Inc., a biotech firm based in the United States, obtained approval from the U.S. Food and Drug Administration in November 2024 for Attruby (acoramidis) to treat adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This helps stabilize the TTR protein and reduces cardiovascular-related fatalities and hospitalizations. Clinical tests have demonstrated that it is easily tolerated and offers quick benefits by addressing the root cause of the disorder.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

Which regions are emerging as leaders in the market?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Hepatitis Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: